Walleye Capital
CGON icon

Walleye Capital’s CG Oncology CGON Stock Holding History

Walleye Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-82,265
Closed -$2.01M – 4553
2025
Q1 		$2.01M Sell
82,265
-142,315
-63% -$4M 0.01% 1409
2024
Q4 		$6.44M Buy
+224,580
New +$7.68M 0.02% 916
2024
Q3 		– Sell
-211,006
Closed -$6.66M – 5346
2024
Q2 		$6.66M Buy
211,006
+104,687
+98% +$3.63M 0.01% 1062
2024
Q1 		$4.67M Buy
+106,319
New +$4.34M 0.01% 1344

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's CGON Position: Q2 2025 in Review

Walleye Capital sold out of CG Oncology (CGON) in Q2 2025, closing a stake of 82,265 shares — an estimated $2.01M sold.

Walleye Capital first reported a position in CGON in Q1 2024 and held it in 4 quarters. The position peaked at $6.66M in Q2 2024. 162 funds tracked by Wall St. Rank hold CGON as of Q2 2025.

  • Walleye Capital reported no remaining CG Oncology position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 82,265 CG Oncology shares in Q2 2025, an estimated $2.01M.
  • Walleye Capital first reported a position in CG Oncology in Q1 2024 and held it in 4 quarters.
  • Walleye Capital's CG Oncology position peaked at $6.66M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held CG Oncology as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.